DDInter380 DDInter899
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Cimetidine {u} (Compound) treats {v} (Disease) obesity
Cimetidine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Cimetidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Cimetidine {u} (Compound) downregulates {v} (Gene) COTL1
Cimetidine {u} (Compound) causes {v} (Side Effect) Flatulence
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quinestrol
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indomethacin
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Cimetidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Cimetidine (Compound) treats obesity (Disease)
Cimetidine (Compound) binds CYP3A7-CYP3A51P (Gene)
Cimetidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Cimetidine (Compound) downregulates COTL1 (Gene)
Cimetidine (Compound) causes Flatulence (Side Effect)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Indomethacin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib